AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21553292 — intervention group
Group type: COMPARATOR
Intervention: TFAC after BCT
Number of subjects: 511
Study 21553292 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC after M
Number of subjects: 511
Study 21553292 — intervention group
Group type: COMPARATOR
Intervention: TFAC after M
Number of subjects: 511
Study 21553292 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC after M + RT
Number of subjects: 511
Study 21553292 — intervention group
Group type: COMPARATOR
Intervention: TFAC after M + RT
Number of subjects: 511
Study 21553292 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 511
Study 21553292 — intervention group
Group type: COMPARATOR
Intervention: TFAC
Number of subjects: 511
Study 19521932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of 20 ml of bone marrow cells (BMC) to the infarct-related artery (IRA) after primary PCI
Number of subjects: 40
Study 19521932 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stenting of IRA without BMC administration
Number of subjects: 40
Study 17544861 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu‐TENS applied to bilateral PC6 (Protocol A)
Number of subjects: 28
Study 17544861 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu‐TENS applied to bilateral PC6 (Protocol B)
Number of subjects: 28
Study 17544861 — intervention group
Group type: COMPARATOR
Intervention: Placebo Acu‐TENS (Protocol C)
Number of subjects: 28
Study 15385375 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose calcium (15 mmol/h)
Number of subjects: 25
Study 15385375 — intervention group
Group type: COMPARATOR
Intervention: Small-dose calcium (5 mmol/h)
Number of subjects: 25
Study 11475845 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ulcerative colitis
Number of subjects: 42
Study 11475845 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with active ulcerative colitis
Number of subjects: 42
Study 11475845 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2‐M activity below 100%
Number of subjects: 42
Study 11475845 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with inflammatory process beyond sigmoid
Number of subjects: 42
Study 11475845 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 42
Study 9790438 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with SPf66
Number of subjects: 69
Study 9790438 — intervention group
Group type: COMPARATOR
Intervention: Control (no immunization)
Number of subjects: 69
Study 7608434 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass operation
Number of subjects: 838
Study 10149758 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour group (n = 43)
Number of subjects: 88
Study 10149758 — intervention group
Group type: COMPARATOR
Intervention: Flat group (n = 45)
Number of subjects: 88
Study 10149758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 396659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (150 mg daily)
Number of subjects: 55
Study 396659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 55
Study 396659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31158369 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hemoclips
Number of subjects: 1098
Study 31158369 — intervention group
Group type: COMPARATOR
Intervention: No hemoclips
Number of subjects: 1098
Study 28146459 — intervention group
Group type: COMPARATOR
Intervention: Control group (parent/guardian verbally informed about the anaesthetic procedure)
Number of subjects: 84
Study 28146459 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed group (parent/guardian verbally informed and provided with an information leaflet)
Number of subjects: 84
Study 28146459 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone group (parent/guardian verbally informed and child received a smartphone application)
Number of subjects: 84
Study 28146459 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone and informed group (parent/guardian received an information leaflet and child received a smartphone application)
Number of subjects: 84
Study 26452342 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral switch therapy (OST)
Number of subjects: 430
Study 26452342 — intervention group
Group type: COMPARATOR
Intervention: Intravenous standard therapy (IST)
Number of subjects: 430
Study 23842564 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive life plan (RLP)-based information provided orally and in writing during contraceptive counselling.
Number of subjects: 299
Study 23842564 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (CG1) received standard care without RLP-based information.
Number of subjects: 299
Study 23842564 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (CG2) received standard care without RLP-based information.
Number of subjects: 299
Study 20299956 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated pneumococcal vaccine (CPV) + polysaccharide pneumococcal vaccine (PPV)
Number of subjects: 202
Study 20299956 — intervention group
Group type: COMPARATOR
Intervention: Polysaccharide pneumococcal vaccine (PPV) alone
Number of subjects: 202
Study 19271025 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 60 mg/day divided into three doses for 6 months
Number of subjects: 32
Study 16882180 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines on the management of psoriasis in primary care and practice‐based nurse‐led training sessions
Number of subjects: 196
Study 16882180 — intervention group
Group type: COMPARATOR
Intervention: No guidelines or training sessions
Number of subjects: 196
Study 12922095 — intervention group
Group type: EXPERIMENTAL
Intervention: 7VPnC plus DTaP‐IPV‐Hib vaccines
Number of subjects: 231
Study 12922095 — intervention group
Group type: COMPARATOR
Intervention: DTaP‐IPV‐Hib vaccine plus 7VPnC catch-up vaccination
Number of subjects: 231
Study 11095261 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2 antisense oligonucleotides (augmerosen) plus standard dacarbazine treatment
Number of subjects: 14
Study 11095261 — intervention group
Group type: COMPARATOR
Intervention: BCL2 antisense oligonucleotides (augmerosen)
Number of subjects: 14
Study 8797612 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg BAY x 1351
Number of subjects: 564
Study 8797612 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg BAY x 1351
Number of subjects: 564
Study 8797612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 1523304 — intervention group
Group type: EXPERIMENTAL
Intervention: In-111 CYT-103
Number of subjects: 227
Study 1523304 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 227
Study 6086371 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser stimulation (50 ms duration, radiant heat pulses between 5 to 20 W)
Number of subjects: 0
Study 6086371 — intervention group
Group type: EXPERIMENTAL
Intervention: Single unit discharges
Number of subjects: 0
Study 30729631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture coupled with a diagnostic workshop (LW)
Number of subjects: 0
Study 30729631 — intervention group
Group type: COMPARATOR
Intervention: Lecture (L)
Number of subjects: 0
Study 29648580 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg for 14 days) plus hypofractionated radiotherapy (40 Gy in 15 fractions)
Number of subjects: 75
Study 29648580 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated radiotherapy (40 Gy in 15 fractions) without bevacizumab
Number of subjects: 75
Study 29648580 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus hypofractionated radiotherapy
Number of subjects: 75
Study 29648580 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated radiotherapy without bevacizumab
Number of subjects: 75
Study 29648580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox model of OS controlling for established prognostic factors
Number of subjects: 75
Study 29648580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox model of OS including molecular subtypes
Number of subjects: 75
Study 27189086 — intervention group
Group type: COMPARATOR
Intervention: Daily prednisone (1-2 mg/kg/day for 2-4 weeks with subsequent dose reduction)
Number of subjects: 26
Study 27189086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dexamethasone (0.6 mg/kg/day, days 1-4 for six 3-week cycles)
Number of subjects: 26
Study 27189086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dexamethasone
Number of subjects: 26
Study 27189086 — intervention group
Group type: COMPARATOR
Intervention: Daily prednisone
Number of subjects: 26
Study 24532031 — intervention group
Group type: EXPERIMENTAL
Intervention: Segment algorithm for perfusion analysis
Number of subjects: 492
Study 22855333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4800 IU/d
Number of subjects: 163
Study 22855333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 20592647 — intervention group
Group type: COMPARATOR
Intervention: R-methamphetamine (R-MA) 0 mg
Number of subjects: 8
Study 20592647 — intervention group
Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA) 1 mg
Number of subjects: 8
Study 20592647 — intervention group
Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA) 2.5 mg
Number of subjects: 8
Study 20592647 — intervention group
Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA) 5 mg
Number of subjects: 8
Study 20592647 — intervention group
Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA) 10 mg
Number of subjects: 8
Study 20592647 — intervention group
Group type: EXPERIMENTAL
Intervention: R-methamphetamine (R-MA-d3) 2.5 mg (IV)
Number of subjects: 8
Study 17296648 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole, 40 mg bid
Number of subjects: 15
Study 17296648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17530947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-trampoline (MT) training for 6 weeks
Number of subjects: 20
Study 17530947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dura disc (DT) training for 6 weeks
Number of subjects: 20
Study 17530947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 15196106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 187
Study 15196106 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus technique (bolus)
Number of subjects: 187
Study 10690697 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of external hip protectors and encouragement to use the protectors by an adherence nurse
Number of subjects: 131
Study 10690697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 131
Study 10690697 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of external hip protectors
Number of subjects: 131
Study 9354200 — intervention group
Group type: EXPERIMENTAL
Intervention: O 20 mg b.d. + C 500 mg b.d. + A 1 g b.d. for 7 days (OAC)
Number of subjects: 302
Study 9354200 — intervention group
Group type: EXPERIMENTAL
Intervention: O 20 mg b.d. + C 250 mg b.d. + M 500 mg b.d. for 7 days (MOC)
Number of subjects: 302
Study 9354200 — intervention group
Group type: EXPERIMENTAL
Intervention: C 250 mg b.d. + M 500 mg b.d. for 7 days (CM)
Number of subjects: 302
Study 9354200 — intervention group
Group type: EXPERIMENTAL
Intervention: A 1 g b.d. + clarithromycin (C) 500 mg b.d. for 7 days (AC)
Number of subjects: 302
Study 9354200 — intervention group
Group type: EXPERIMENTAL
Intervention: O 20 mg b.d. + amoxycillin (A) 1 g t.d.s. for 14 days (OA)
Number of subjects: 302
Study 7692146 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine GITS
Number of subjects: 394
Study 7692146 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 394
Study 3333018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 60
Study 3333018 — intervention group
Group type: COMPARATOR
Intervention: Calcium infusions
Number of subjects: 60
Study 3333018 — intervention group
Group type: COMPARATOR
Intervention: 1 alpha-hydroxyvitamin D3
Number of subjects: 60
Study 30922759 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aortic aneurysm repair (EVAR) for intact AAA
Number of subjects: 19336
Study 30922759 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative predictors of 1-year mortality
Number of subjects: 19336
Study 30922759 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative statin use
Number of subjects: 19336
Study 30922759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model performance
Number of subjects: 19336
Study 28540452 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Driving Simulation Training (VRDST)
Number of subjects: 51
Study 28540452 — intervention group
Group type: COMPARATOR
Intervention: Routine Training (RT)
Number of subjects: 51
Study 25834594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-hydroxyapatite (NHA)
Number of subjects: 20
Study 25834594 — intervention group
Group type: COMPARATOR
Intervention: Calcium-enriched mixture (CEM)
Number of subjects: 20
Study 24793366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (succinylnorcocaine conjugated to cholera toxin B protein)
Number of subjects: 300
Study 24793366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24793366 — intervention group
Group type: EXPERIMENTAL
Intervention: High IgG group (≥42 μg/mL)
Number of subjects: 300
Study 24793366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 300
Study 24793366 — intervention group
Group type: COMPARATOR
Intervention: Vaccine and Placebo
Number of subjects: 300
Study 23025511 — intervention group
Group type: EXPERIMENTAL
Intervention: OC000459 200 mg bid
Number of subjects: 35
Study 23025511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19142771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramids and Palm Trees Test (PPT)
Number of subjects: 0
Study 17336224 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 10
Study 17336224 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 10
Study 17336224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DTRUS imaging
Number of subjects: 10
Study 17336224 — intervention group
Group type: COMPARATOR
Intervention: CT/MR comparison
Number of subjects: 10
Study 17336224 — intervention group
Group type: COMPARATOR
Intervention: 3DTRUS/MR comparison
Number of subjects: 10
Study 17336224 — intervention group
Group type: COMPARATOR
Intervention: CT/3DTRUS comparison
Number of subjects: 10
Study 15449264 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete enteral nutrition
Number of subjects: 18
Study 15449264 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric nutrition
Number of subjects: 18
Study 11403182 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-labeled peptide P483H (29 microg, n = 11; 145 microg, n = 10; 290 microg, n = 9)
Number of subjects: 30
Study 11403182 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-labeled peptide P483H
Number of subjects: 30
Study 11403182 — intervention group
Group type: COMPARATOR
Intervention: In vitro-labeled leukocyte scintigraphy (n = 20)
Number of subjects: 30
Study 9489266 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs
Number of subjects: 0
Study 9489266 — intervention group
Group type: COMPARATOR
Intervention: Alternative research approaches
Number of subjects: 0
Study 7803209 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate 0.1 mg s.c. 45 minutes before ERCP, followed by another dose 6 hours later.
Number of subjects: 100
Study 7803209 — intervention group
Group type: COMPARATOR
Intervention: Placebo s.c.
Number of subjects: 100
Study 3149400 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 12
Study 3149400 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 31344519 — intervention group
Group type: EXPERIMENTAL
Intervention: Single level intervention delivered only to the adolescent (AO)
Number of subjects: 114
Study 31344519 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention delivered to both the adolescent and a parent (A + P)
Number of subjects: 114
Study 31344519 — intervention group
Group type: COMPARATOR
Intervention: Both AO and A + P groups
Number of subjects: 114
Study 28154996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanostructured calcium‐incorporated (NCI) implants
Number of subjects: 15
Study 28154996 — intervention group
Group type: COMPARATOR
Intervention: Machined (MA) implants
Number of subjects: 15
Study 28154996 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NCI and MA implants
Number of subjects: 15
Study 25257978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and cognitive behavioral therapy
Number of subjects: 349
Study 23442255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 117
Study 23442255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (2,400 mg/day)
Number of subjects: 117
Study 23442255 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 20688474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg twice daily)
Number of subjects: 0
Study 20688474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU twice daily)
Number of subjects: 0
Study 19748402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Compression (IC) treatment for MTrPs
Number of subjects: 66
Study 19748402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) treatment for MTrPs
Number of subjects: 66
Study 19748402 — intervention group
Group type: COMPARATOR
Intervention: Sham Ultrasound (Control)
Number of subjects: 66
Study 16703539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.02%
Number of subjects: 62
Study 14984378 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 31
Study 14984378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12765427 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via Clickhaler DPI (0, 100, 200, or 400 microg)
Number of subjects: 18
Study 12765427 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via Ventolin pMDI (0, 100, 200, or 400 microg)
Number of subjects: 18
Study 10945088 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant trials with improved blindness procedures
Number of subjects: 0
Study 10945088 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled studies
Number of subjects: 0
Study 9127371 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm/day ceftriaxone
Number of subjects: 90
Study 9127371 — intervention group
Group type: COMPARATOR
Intervention: 2 million U penicillin G every 4 hours
Number of subjects: 90
Study 9127371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 90
Study 9127371 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 90
Study 1550533 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal scopolamine
Number of subjects: 21
Study 1550533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3545883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 120 mg daily
Number of subjects: 97
Study 3545883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 60 mg daily
Number of subjects: 97
Study 3545883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 30367613 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-based mobile intervention (MyTeen) for parents, tailored programme of text messages over 4 weeks
Number of subjects: 214
Study 30367613 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 214
Study 30367613 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-based mobile intervention (MyTeen)
Number of subjects: 214
Study 27753434 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on clear liquid diet (4-min video provided 48-72 hours before CLS)
Number of subjects: 92
Study 27753434 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-procedure instructions (no video)
Number of subjects: 92
Study 25535596 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher left ventricular ejection fraction (LVEF) associated with female sex and greater BMI
Number of subjects: 151
Study 25535596 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower left ventricular ejection fraction (LVEF) associated with pacemaker/defibrillator use and methamphetamine use
Number of subjects: 151
Study 22240792 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab (Bev) 5 mg kg(‐1) every 2 weeks (Arm-A)
Number of subjects: 333
Study 22240792 — intervention group
Group type: COMPARATOR
Intervention: CAPIRI plus bevacizumab (Bev) 7.5 mg kg(‐1) every 3 weeks (Arm-B)
Number of subjects: 333
Study 22240792 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPIRI plus bevacizumab (Bev)
Number of subjects: 333
Study 21349059 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised STRICTA checklist for acupuncture reporting guidelines
Number of subjects: 47
Study 21349059 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised STRICTA checklist
Number of subjects: 47
Study 21349059 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration between STRICTA Group, CONSORT Group, and Chinese Cochrane Centre
Number of subjects: 47
Study 18691392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer plus theory-based intervention (with 20% monthly increase target)
Number of subjects: 54
Study 18691392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer plus theory-based intervention (with 10% and 15% monthly increase targets)
Number of subjects: 54
Study 18691392 — intervention group
Group type: COMPARATOR
Intervention: Theory-based intervention alone
Number of subjects: 54
Study 18691392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer group overall
Number of subjects: 54
Study 18691392 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 54
Study 15850917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.8 mg, orally once a day)
Number of subjects: 126